An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer

BACKGROUND: KRAS mutations are the most frequent oncogenic aberration in lung adenocarcinoma. KRAS mutant isoforms differentially shape tumour biology and influence drug responses. This heterogeneity challenges the development of effective therapies for patients with KRAS-driven non-small cell lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haiyun, Lv, Qi, Xu, Yue, Cai, Zhaoqing, Zheng, Jie, Cheng, Xiaojie, Dai, Yao, Jänne, Pasi A., Ambrogio, Chiara, Köhler, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945285/
https://www.ncbi.nlm.nih.gov/pubmed/31668570
http://dx.doi.org/10.1016/j.ebiom.2019.10.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945285/
https://www.ncbi.nlm.nih.gov/pubmed/31668570
http://dx.doi.org/10.1016/j.ebiom.2019.10.012

Ejemplares similares